ClinicalTrials.gg
Sign In
Status unknownNCT02934594Updated Oct 17, 2016

Metastatic Spinal Cord Compression (MSCC): Treatment Timing and Survival Rate

An observational study in Neoplasm Metastasis and Spinal Cord Compression, sponsored by National Taiwan University Hospital. Status unknown. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-10-17.

Sponsored by National Taiwan University Hospital · Observational

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-only
Enrollment
500
Ages
21 Years to 99 Years
Sex
All
01

Study summary

Patients with metastatic spinal cord compression (MSCC) are treated with different options according to the life expectancy. Survival and surgical outcome can be influenced by surgical timing in MSCC patients treated with palliative decompression.

Read the detailed description

MSCC patients who underwent palliative decompression after January 2012 in National Taiwan University Hospital (NTUH) were divided into the preoperative motor function intact group (Group A) and motor deficit group (Group B). The motor deficit group was subdivided into operation within 48 hours (Group B1), and after 48 hours (Group B2). All patients underwent palliative decompression and posterior stabilization. Investigators did wide laminectomy for tumor invading the vertebral body, and debulking surgery for tumor destructing the posterior column of the spine. Investigators retrospectively reviewed all patient records, including patient demographics, prognostic factors for survival (Kaplan-Meier survival analysis), neurological outcome (Frankel grade), primary tumor, complications, and relevance of Tomita and Tokuhashi scores.

02

Conditions studied

  • Neoplasm Metastasis
  • Spinal Cord Compression
03

In context

Neoplasm Metastasis

4,040 studies on the registry are indexed under Neoplasm Metastasis; 886 are open to participants now.

This study's planned enrollment of 500 is above the median of 136 across 557 observational studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Browse National Taiwan University Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with metastatic spinal cord compression (MSCC) who underwent palliative decompression.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with spinal cord compression (MSCC) who underwent palliative decompression in National Taiwan University Hospital after January 1st, 2012.

Exclusion criteria

Exclusion Criteria:

  • Patients with spinal cord compression (MSCC) who underwent palliative decompression before December 31st, 2011, or those who were not treated in National Taiwan University Hospital.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Enrollment
500 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Group A

    Motor function intact group: received palliative decompression

    Other: Palliative Decompression

  • Group B1

    motor deficit group: received palliative decompression within 48 hours after symptoms occured

    Other: Palliative Decompression

  • Group B2

    motor deficit group: received palliative decompression 48 hours after symptoms occured

    Other: Palliative Decompression

Interventions

  • OtherPalliative Decompression

    palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)

06

What researchers measure

Primary outcomes

  1. survival rate

    Time frame: 5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 2005 Oct 1;30(19):2186-91. doi: 10.1097/01.brs.0000180401.06919.a5. PubMed 16205345 ↗
  • Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine (Phila Pa 1976). 2001 Feb 1;26(3):298-306. doi: 10.1097/00007632-200102010-00016. PubMed 11224867 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2016, a primary completion of Aug 2020 and a completion of Aug 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2016
First posted
Oct 17, 2016
Start
Oct 2016
Primary completionEst.
Aug 2020
CompletionEst.
Aug 2020
Last update
Oct 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02934594
Lead sponsor
National Taiwan University Hospital
Responsible party
Sponsor
First posted
Oct 17, 2016
Start date
Oct 2016
Primary completion
Aug 2020 (estimated)
Completion
Aug 2020 (estimated)
Last update
Oct 17, 2016

Study contacts

Shu-Hua Yang, M.D., Ph.D.
Contact
005964@ntuh.gov.tw
886-2-23123456 ext. 63981
Shu-Hua Yang, M.D., Ph.D.
study chair · National Taiwan University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasm Metastasis →

Other studies from this sponsor

National Taiwan University Hospital →

Start the discussion